Evidence map›Paper›PMID 37999107›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

High Expression of Fas-Associated Factor 1 Indicates a Poor Prognosis in Non-Small-Cell Lung Cancer.

De Hu, Hidetaka Yamada, Katsuhiro Yoshimura, Tsutomu Ohta, Kazuo Tsuchiya, Yusuke Inoue, Kazuhito Funai, Takafumi Suda, Yuji Iwashita, Takuya Watanabe and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

De HuDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Hidetaka YamadaDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0003-4848-7201
Katsuhiro YoshimuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Tsutomu OhtaDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Kazuo TsuchiyaDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Yusuke InoueDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Kazuhito FunaiFirst Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0001-8609-3305
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Yuji IwashitaDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0002-9085-5429
Takuya WatanabeDivision of Thoracic Surgery, Department of Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu 433-8558, Shizuoka, Japan.
Hiroshi OgawaDepartment of Pathology, Seirei Mikatahara General Hospital, Hamamatsu 433-8558, Shizuoka, Japan.ORCID 0000-0003-0236-6535
Nobuhito KuronoDepartment of Chemistry, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Kazuya ShinmuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.
Haruhiko SugimuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0002-0779-3088
Hamamatsu University School of Medicine · JPSeirei Mikatabara General Hospital · JPSasaki Institute · JPTokoha Gakuen University · JP

Funding

Smoking Research Foundation 2019T009
6 · The paper itself

Abstract

Fas-associated factor 1 (FAF1) is a death-promoting protein identified as an interaction partner of the death receptor Fas. The downregulation and mutation of FAF1 have been reported in a variety of human tumors, but there have been few studies on lung cancer. Here, we investigated the prognostic significance of FAF1 expression in non-small-cell lung cancer (NSCLC), and whether aberrant FAF1 expression may be involved in the pathogenesis and prognosis of NSCLC. FAF1 expression was examined in NSCLC specimens as well as human lung cancer cell lines. In addition, changes in cell viability and apoptosis upon regulating FAF1 expression were investigated in lung cancer cell lines. As a result, high FAF1 expression was significantly associated with a poor prognosis in NSCLC. In lung cancer cell lines, FAF1 downregulation hindered cell viability and tended to promote early apoptosis. In conclusion, this is the first study of the clinical significance of FAF1 in NSCLC, showing that FAF1 overexpression is associated with a poor prognosis in NSCLC and that FAF1 acts as a dangerous factor rather than an apoptosis promoter in NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsCarrier ProteinsFibrinogenHumansPrognosisAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsCarrier ProteinsFAF1 protein, humanFibrinogenapoptosisFAF1non-small-cell lung cancerprognosisproliferation

Identifiers

PMID37999107
PMCPMC10670600
OpenAlexW4388267794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.